Are Your Granted Patents in Danger of a Post-Grant Double Patenting Challenge?
From Academia to the Marketplace: The Ins and Outs of University Spinout Licenses with Dan O’Korn
Nonpublication Requests For Patent Applications: Disadvantages
Podcast: Blockchain Intellectual Property Considerations for Innovators and Investors
Enforcement Challenges For Biotech Patents
Is the Patent Litigation Boom Coming to an End?
Patent Series: Protecting inventions
Kevin DeJong (Senior Editor) and Shweta Kumar (Editor) from the Big Molecule Watch recently interviewed Rachel Goode, Ph.D. to discuss an article she recently co-authored, “Biological patent thickets and delayed access to...more
This year, the BPCIA turns 10! As we prepare to enter the next decade of this revolutionary law, we cordially invite you to join us for ACI’s 11th Annual Biosimilars & Innovator Biologics Summit, in a fully virtual,...more
A federal district court recently dismissed a lawsuit against AbbVie and biosimilar manufacturers of adalimumab involving a novel antitrust claim against the Humira patent estate. Attorneys with Haug Partners LLP take an...more
Last week, Merck announced its intention to spin-off products from its Women’s Health, legacy brands, and biosimilars businesses into a new, yet-to-be-named, independent, publicly traded company. According to Merck, “NewCo...more
To date, Amgen has been the reference product sponsor for many biosimilar applications. Correspondingly, Amgen has been the Plaintiff in many of the litigations that have been based on the provisions of the Biosimilar Price...more